Related Experiment Videos
Phase I study of tauromustine administered in a weekly schedule
S B Gjedde1, H T Mouridsen, E L-Madsen
1Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1993
Summary
This study investigated oral tauromustine for melanoma, finding a weekly dose of 35 mg/m2/week is well-tolerated. This dosing schedule increases treatment intensity without significantly raising toxicity in patients with disseminated malignant melanoma.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Disseminated malignant melanoma presents a significant treatment challenge.
- Optimizing chemotherapy dosing is crucial for improving patient outcomes.
Purpose of the Study:
- To determine the safety and tolerability of orally administered tauromustine in patients with disseminated malignant melanoma.
- To establish a long-term tolerated dose and evaluate dose-intensity increases with a weekly dosing schedule.
Main Methods:
- Weekly oral administration of tauromustine with interindividual dose escalation.
- Dose levels ranged from 20 mg/m2/week, escalating by 5 mg/m2/week, up to a limit of 55 mg/m2/week.
- Toxicity was evaluated in 99 patients who completed at least 8 weeks of treatment across eight dose levels.
Main Results:
- Reversible thrombocytopenia and leukopenia were identified as dose-limiting toxicities.
- The long-term tolerated dose was determined to be 35 mg/m2/week, starting from an initial dose of 40 mg/m2/week.
- The weekly schedule allowed for increased dose intensity without a significant rise in toxicity.
Conclusions:
- Weekly oral tauromustine is a viable treatment option for disseminated malignant melanoma.
- A dose of 35 mg/m2/week represents a safe and effective long-term tolerated dose.
- This dosing strategy enhances treatment intensity, potentially improving therapeutic efficacy in melanoma patients.